Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 13

TGF-β1 Gene Polymorphism and Its Correlation with Serum Level of TGF-β1 in Psoriasis Vulgaris Among Iraqi People

Authors Ahmed BT, Saeed MY, Noori SH, Amin DM

Received 16 September 2020

Accepted for publication 18 November 2020

Published 24 November 2020 Volume 2020:13 Pages 889—896


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Jeffrey Weinberg

Bryar T Ahmed,1 Mohammad Y Saeed,1 Saman H Noori,2 Dashty M Amin3

1Department of Medicine/Dermatology, College of Medicine, University of Sulaimani, Sulaimani City, Kurdistan, Iraq; 2Department of Biochemistry, College of Medicine, University of Sulaimani, Sulaimani City, Kurdistan, Iraq; 3Medical Laboratory Sciences, Komar University of Science and Technology, Sulaimani City, Kurdistan, Iraq

Correspondence: Bryar T Ahmed
Department of Medicine/Dermatology, College of Medicine, University of Sulaimani, P.O Box 97, Hawarabarza, Sulaimani City, Iraq
Tel +9647701520468

Purpose: Many cytokines have been implicated in the pathogenesis of psoriasis, among these the transforming growth factor-beta 1 (TGF-β 1) can be endorsed by different mechanisms besides inhibiting keratinocytes proliferation. The role of genetic polymorphisms of TGF-β 1 has been studied in various inflammatory diseases. Our aim is to study the correlation of TGF-β 1 gene polymorphism at codon 10 and 25 with the expression of serum level of TGF-β 1 in a sample of Iraqi psoriatic patients compared to the control group.
Materials and Methods: A cross-sectional study involved 100 patients with psoriasis vulgaris and 50 sex- and age-matched healthy volunteers as control group. Serum and genomic DNA were prepared from peripheral blood samples. Amplification refractory mutation system–polymerase chain reaction technique (ARMS-PCR) had been applied for genotyping TGF-β 1 codon 10 [rs1982073] and codon 25 [rs1800471] genetic polymorphisms. Enzyme-linked immunosorbent assay technique (ELISA) based on the sandwich principle was used for quantification of serum TGF-β 1 level. Psoriasis Area and Severity Index (PASI) scoring was applied for determining the severity in psoriatic patients and classified accordingly to mild (PASI< 7), moderate (PASI 7– 12), severe (PASI> 12) groups.
Results: Statistically significant difference was found in TGF-β 1 gene polymorphism between psoriatic patients and control group at codon 10 (T869C) polymorphism (p=0.021) and codon 25 (G915C) polymorphism (p=0.040). No significant association was detected with the mean serum TGF-β 1 level, severity of the disease, disease onset, gender, history of psoriatic arthritis, and smoking in both codons. Significant lower mean serum TGF-β 1 level was found among psoriatic group (192.17 ± 531.12 ng/L) compared with controls (565.89 ± 1372.30 ng/L) (p = 0.018). Relation of mean serum TGF-β 1 level with the onset of the disease was statistically significant (p = 0.004), early-onset disease group was lower (105.92 ± 68.02 ng/L) compared with the late-onset disease group (450.92 ± 1027.79 ng/L). The mean serum TGF-β 1 level showed no significant differences with the severity of psoriasis, gender, history of psoriatic arthritis, and smoking.
Conclusion: Iraqi population showed a significant association between TGF-β 1 gene polymorphism at codon 10 and 25 were with psoriasis susceptibility, and a significantly lower mean serum TGF-β 1 level was detected in psoriatic patients.

Keywords: psoriasis, TGF-β 1, gene, polymorphism

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]